VAUDREUIL-DORION, QUEBEC–(Marketwired – May 18, 2017) – Immunotec Inc. (TSX VENTURE:IMM), a direct-to-consumer company and a leader in the nutritional industry (the “Company” or “Immunotec”), today announced that it has completed its previously announced going-private transaction by way of a plan of arrangement under the Canada Business Corporations Act (the “Arrangement”) pursuant to which 1111267 B.C. Ltd., a subsidiary of Immuno Holding, S.A. de C.V (together, “Immuno Holding”), acquired all of the issued and outstanding common shares of the Company (“Shares”) for a cash consideration of $0.485 per Share.
“As a new member of the Immunotec family, I look forward to working collaboratively with Immunotec’s management and employees in Quebec, the U.S. and Mexico, as well as with its network of over 100,000 independent consultants, to fuel Immunotec’s growth”, said Mauricio Domenzain, leader of Immuno Holding. “Together, we will carry on the vision shared by the Company’s founders and Dr. Gustavo Bounous to position Immunocal® as a global nutritional choice and to continue to improve the lives of many more with this outstanding product.”
Charlie Orr, CEO of Immunotec, added: “As Immunotec celebrated last year its 20th year of commercialization and 40 years of research, this transaction represents an exciting new chapter in the history of Immunotec and in its continued path of growth and success.”
In order to receive the consideration for their Shares payable pursuant to the Arrangement, registered shareholders of Immunotec must complete and sign the Letter of Transmittal sent to them with the management information circular for the special meeting of Immunotec shareholders held on May 11, 2017 and deliver such Letter of Transmittal to Computershare Trust Company of Canada (the “Depositary”) together with certificates representing their Shares and such additional documents and instruments as the Depositary may reasonably require. A copy of the Letter of Transmittal may also be obtained by contacting the Depositary and is available on SEDAR at www.sedar.com under Immunotec’s profile. Any questions regarding the payment of the consideration, including any request for another copy of the Letter of Transmittal, should be directed to the Depositary by telephone at 1-800-564-6253 or by e-mail at email@example.com.
Shareholders whose Shares are registered in the name of a broker, investment dealer, bank, trust company, trustee or any other similar intermediary entity (together, an “Intermediary”), custodian or nominee, should contact that Intermediary, custodian or nominee for assistance in depositing their Shares and should follow the instructions of such Intermediary, custodian or nominee in order to deposit their Shares.
As a result of the completion of the Arrangement, transactions in the Shares will be halted at the opening of the market on May 18, 2017, and it is expected that the Shares will be delisted from the TSX Venture Exchange shortly thereafter. The Company has applied to the relevant securities regulatory authorities in Canada to cease to be a reporting issuer for the purposes of securities legislation.